Table 1

EC0746 anti-arthritis activity in comparison with methotrexate and etanercept

Treatment

Dose

Frequency

Inhibition in paw edema (%)^a

Splenomegaly^b

Body weight change (%)^c

Control

-

-

0

117 ± 22

-16 ± 1

EC0746 (s.c.)

25 nmol/kg

Biweekly

0 ± 25^d

73 ± 8^e

-17 ± 1

100 nmol/kg

Biweekly

35 ± 11^d

52 ± 13^e

-14 ± 1

250 nmol/kg

Biweekly

91 ± 4^d

25 ± 6^e

-0.5 ± 3

500 nmol/kg

Biweekly

91 ± 9

37 ± 7

0.4 ± 4

1,000 nmol/kg

Once weekly

72 ± 12

39 ± 5

-7 ± 3

MTX (p.o.)

250 nmol/kg

Biweekly

70 ± 5

42 ± 17

-14 ± 2

1,650 nmol/kg

Once weekly

47 ± 10^f

-

-10 ± 2

MTX (s.c.)

250 nmol/kg

Biweekly

78 ± 10

24 ± 3

-2 ± 4

1,650 nmol/kg

Once weekly

63 ± 13^f

-

-7 ± 8

Etanercept (s.c.)

10 mg/kg

Every 3 days

46 ± 9^f

42 ± 7

-15 ± 2

Rats with adjuvant arthritis were treated at disease onset (10 days post arthritis induction) with EC0746, methotrexate (MTX), and etanercept at indicated doses, dosing routes, and dosing frequencies. s.c., subcutaneously; p.o., per orally. ^aInhibition in paw edema is calculated based on paw weight on day 24: 100 × (arthritic control - treated)/(arthritic control - healthy). ^bSplenomegaly is defined as the percentage increase in spleen weight relative to the spleen weights of healthy rats. ^cOn day 24 relative to body weight on the first day of treatment (day 10). Linear regression analysis: ^dR² = 1.00 (paw) and ^eR² = 0.99 (spleen). ^fCalculated based on arthritis scores on day 24 (paw weights were not obtained).

Lu et al. Arthritis Research & Therapy 2011 13:R56   doi:10.1186/ar3304